We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic-Based Risk Test for Colorectal Cancer Being Developed

By LabMedica International staff writers
Posted on 19 May 2011
The development of a new genetic-based risk assessment test for colorectal cancer with clinical validation is being supported by collaboration between two companies.

Bar Harbor BioTechnology (BHB; Trenton, Maine, USA), Inc. More...
and Clinical Reference Laboratory, Inc. (CRL; Lenexa, Kansas, USA) have announced the collaboration, which involves the continued development of BHB's new genetic-based test for colorectal cancer risk with clinical validation support provided by CRL's CLIA-certified laboratory services.

CRL will provide laboratory-testing services in molecular diagnostics and clinical trials of the new test. The new arrangement will give CRL and BHB the opportunity to combine BHB's bioinformatics and quantitative polymerase chain reaction (qPCR) assay development team with CRL's extensive molecular lab testing experience to create new molecular diagnostic tests.

Further details of the tests remain undisclosed but both companies indicate that the agreement envisions future projects and the development of additional tests. "CRL is an ideal partner for our company as we continue to develop our risk assessment tests. Their CLIA-certified testing services accelerate our development plans by leveraging on their expertise and state of the art laboratory; we will get the results we need immediately," said Robert Phelps, CEO of BHB.

Bar Harbor BioTechnology manufactures software and consumables for purposes of genetic research in areas of cancer, stem cell research, immunology, metabolism, and specific neurological disorders. The company created a new diagnostic division in 2010.

CRL is a privately held reference laboratory offering testing services in the areas of clinical trials, corporate wellness programs, genomics, insurance, molecular diagnostics, bioanalytics, and toxicology.

Related Links:

Bar Harbor BioTechnology
Clinical Reference Laboratory




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.